Cellular therapy of T1D with adult stem cells: the challenge of the LSFM4LIFE project

Dr. Francesco Pampaloni, scientific manager and coordinator of the LSFM4LIFE project at Goethe University in Frankfurt, will be performing three talks in March 2017 about cellular therapy for type 1 diabetes (T1D). All those presentations will take place in Italy, in different Hospitals.


In these talks Dr. Pampaloni will further explain further the goal of the LSFM4LIFE project to medical doctors in pediatric hospitals. The cellular therapy with β-cells will be the main theme addressed and we firmly believe that LSFM4LIFE can revolutionize the worldwide incidence of type 1 diabetes (T1D) and therefore become the solution to creating a curative therapy.

Nowadays there is a fundamental issue concerning the type of stem cells used to find a method to cure T1D. While embryonic stem cells (ESC) present important ethical challenges, induced pluripotent stem cells (iPSC) imply a safety issue due to the activation of oncogenes during the reprogramming of somatic cells.

LSFM4LIFE is currently working on an innovative method, which consists of isolating and cultivating pancreas genitor cells (human pancreas organoids), and allows researchers/doctors to overcome the disadvantages of embryonic stem cells and induced pluripotent stem cells.

The first objective of these three seminars is to inform medical doctors about the stem cell organoid technology and the progress of LSFM4LIFE from its beginning, one year ago, until now. We illustrate to the audience our strategy and the challenges until 2020 to achieve the goal of a replacement therapy of beta cells with the pancreas organoids. We will focus especially on these topics:

  • Optical technology for the characterization and quality control of the pancreas organoids
  • Three-dimensional cell culture technology
  • Biomimetic scaffolds optimization
  • Good Manufacturing Practices of pancreas organoid production for clinical testing

The second objective of the seminar is to obtain a feedback from the medical doctors (and particularly from T1D specialists) in order to envision and start planning the clinical testing of the pancreas organoids after 2020.

Francesco Pampaloni’s talks :